A new biomarker, uncovered by researchers in the University of Kentucky College of Pharmacy, could change cardiovascular care for patients with high risk of disease.
What is possible? It is the question that drives and shapes everything we do at the University of Kentucky. It enables us to achieve what we call “wildly possible.”
UK Research had much to celebrate in 2019, growth in research awards—up 25% from FY18 to FY19—to the largest grant in UK’s history, the $87 million HEALing Communities Study from NIH that aims to reduce opioid overdose deaths by 40% in three years.
The UK College of Public Health, in coordination with UofL and the Kentucky Cancer Consortium, have created a worksite intervention on lung cancer, which targets work sites with predominantly male employees in eight rural and medically underserved counties in southern Kentucky.
KY NSF's EPSCoR, has awarded UK, UofL and six other institutions across the state a five-year, $24 million grant to advance next generation manufacturing technologies, flexible electronics and robotics.
Subbarao Bondada, professor of microbiology in the Department of Microbiology, Immunology and Molecular Genetics, has been named a Fellow of the American Association for the Advancement of Science (AAAS).
The UK Office of Technology Commercialization (OTC) worked with four UK innovators to pitch their technologies at the inaugural Founder Hunt event at Churchill Downs in Louisville.
“I saw that there was a mandatory research component, which was a big deal for them and myself. The agricultural biotechnology program emphasizes the independent research project. So, I signed up. It was one of the best decisions I have ever made."
UK is bringing 90 scholars, in diverse academic and scientific disciplines from over 40 countries, to campus in hopes of continuing the conversation surrounding addiction and recovery.
